Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alimera Sciences, Inc. (NASDAQ:ALIM – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 103,900 shares, a decline of 14.6% from the April 30th total of 121,700 shares. Based on an average daily trading volume, of 67,700 […]
AIGH Capital Management LLC lowered its stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,226,068 shares of the biopharmaceutical company’s stock after selling 146,504 […]
Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) – HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their prior forecast […]
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The
StockNews.com lowered shares of Alimera Sciences (NASDAQ:ALIM – Free Report) from a buy rating to a hold rating in a report published on Tuesday morning. Separately, Maxim Group assumed coverage on Alimera Sciences in a report on Monday, March 25th. They set a buy rating and a $10.00 target price on the stock. View Our […]